KROS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KROS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Keros Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 31.15.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Keros Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for Keros Therapeutics's Cash-to-Debt or its related term are showing as below:
During the past 6 years, Keros Therapeutics's highest Cash to Debt Ratio was 526.21. The lowest was 5.51. And the median was 132.50.
The historical data trend for Keros Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Keros Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash-to-Debt | Get a 7-Day Free Trial | 5.51 | 295.75 | 210.47 | 21.04 | 22.93 |
Keros Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash-to-Debt | Get a 7-Day Free Trial | 25.11 | 23.08 | 20.11 | 22.93 | 31.15 |
For the Biotechnology subindustry, Keros Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's Cash-to-Debt falls into.
This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Keros Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 331.147 | / | (1.005 | + | 13.439) | |
= | 22.93 |
Keros Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 442.443 | / | (1.05 | + | 13.154) | |
= | 31.15 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics (NAS:KROS) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thank you for viewing the detailed overview of Keros Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Keith Regnante | officer: Chief Financial Officer | 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
Alpna Seth | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Jennifer Lachey | officer: Chief Scientific Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Christopher Rovaldi | officer: Chief Operating Officer | C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139 |
Julius Knowles | director | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Simon Peter Cooper | officer: Chief Medical Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421 |
Claudia Ordonez | officer: Chief Medical Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Mary Ann Gray | director | 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
Pontifax Management 4 G.p. (2015) Ltd. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Tomer Kariv | director, 10 percent owner | C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
Ran Nussbaum | director, 10 percent owner | C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Jasbir Seehra | director, officer: Chief Executive Officer | C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451 |
Arkin Bio Ventures Limited Partnership | 10 percent owner | 6 HACHOSHLIM STREET, HERZLIYA PITUACH L3 4672406 |
From GuruFocus
By sperokesalga sperokesalga • 04-19-2023
By Value_Insider Value_Insider • 11-07-2022
By Marketwired • 07-24-2023
By Value_Insider Value_Insider • 11-03-2022
By GuruFocusNews GuruFocusNews • 07-01-2022
By Value_Insider Value_Insider • 11-22-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By PurpleRose PurpleRose • 07-11-2022
By sperokesalga sperokesalga • 06-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.